You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • SAT0323 The endothelial-to-mesenchymal transition (ENDOMT) in scleroderma can be prevented by the use of dual endothelin receptor antagonists bosentan and macitentan

Alerts

Article menu

Download PDFPDF

Poster Presentations
Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models
SAT0323 The endothelial-to-mesenchymal transition (ENDOMT) in scleroderma can be prevented by the use of dual endothelin receptor antagonists bosentan and macitentan
Free
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address